Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained.

摘要: Abstract Objective We describe the heterogeneity of estimates incremental cost per quality-adjusted year life (QALY) within and between cost-utility studies human papillomavirus (HPV) vaccine. Method searched for articles in English published peer-reviewed journals that perform analyses to evaluate addition HPV vaccine 12-year-old girls existing cervical cancer screening practices. Fifteen were selected according our inclusion exclusion criteria. Results There are large within-study variations QALY gained. The most influential source uncertainty is duration protection. Between-study mainly due three causes: methodological differences, assumptions, local conditions application area. find a given country. Discussion Economic evaluation models increasingly sophisticated, but scientific treatment epidemiological market does not compensate lack basic information. Conclusions disparities massive vaccination programs around world may be attributed several critical sources (unavoidable avoidable) uncertainty. An asset economic ability highlight areas research could undertaken reduce